$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Reduced calorie fats made from triglycerides containing medium and long chain fatty acids 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A23D-005/00
출원번호 US-0989484 (1992-12-04)
발명자 / 주소
  • Seiden Paul (Cincinnati OH)
출원인 / 주소
  • The Procter & Gamble Company (Cincinnati OH 02)
인용정보 피인용 횟수 : 124  인용 특허 : 0

초록

A reduced calorie fat comprising at least about 15% by weight triglycerides selected from the group consisting of MML, MLM, LLM, and LML triglycerides, and mixtures thereof; wherein M=fatty acids selected from the group consisting of C6 to C10 saturated fatty acids, and mixtures thereof, and L=fatty

대표청구항

A reduced calorie fat having an at least about 10% reduction in calories relative to corn oil and comprising at least about 50% by weight reduced calorie triglycerides selected from the group consisting of MML, MLM, LLM, and LML triglycerides, and mixtures thereof and at least about 10% by weight of

이 특허를 인용한 특허 (124)

  1. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda, Antagonat compositions and methods of use.
  2. Gandhi,Neena, Antioxidant triacylglycerols and lipid compositions.
  3. Nagaoka Shushi,JPX ; Ibuki Masahisa,JPX, Biodegradable lubricant base oil and its manufacturing process.
  4. Cherukuri Subraman R. ; Battist Gerald E. ; Zamudio-Tena Jose F., Comestibles containing stabilized highly odorous flavor component delivery systems.
  5. Nakhasi, Dilip K.; Daniels, Roger L., Composition with health and nutrition promoting characteristics, containing interestified lipids and phytosterol, and related methods.
  6. Nosaka, Naohisa; Ooyama, Katsuhiko; Kojima, Keiichi; Suzuki, Yoshie, Concentrated liquid diet.
  7. Guezennec Yannick (Fontainebleau FRX) Koziet Joseph (Villiers Sur Marne FRX) Thiry Michel (Vigneux Sur Seine FRX), Dietary drink intended to enable sustained activity.
  8. Lin,Peter Yau Tak; Gruber,David Cammiade; Martinez Serna Villagran,Maria Dolores; Seiden,Paul, Emulsifier systems for use in making dehydrated starch ingredients.
  9. Hidaka Hiroshi,JPX ; Inayoshi Kuniaki,JPX ; Nishimoto Tugio,JPX ; Yabuuchi Sayoko,JPX, Fat composition and frothing oil-in-water emulsion.
  10. Del Vecchio Anthony J., Food products containing structured triglycerides.
  11. Aoe Seiichirou,JPX ; Matsuyama Hiroaki,JPX ; Yahagi Sachiko,JPX ; Yahiro Masatoshi,JPX ; Konishi Hiroaki,JPX ; Kameoka Tatsuji,JPX ; Tatsumi Kiyoshi,JPX, Foods and beverages having decreased digestive and absorptive properties.
  12. Kester Jeffrey John ; Elsen Joseph James ; Young Herbert Thomas ; Corrigan Patrick Joseph ; Biedermann David Thomas ; Papa Alyce Johnson, Forced air convection oven process for finishing french fries.
  13. Reed Jada Dawn ; Seiden Paul ; Zimmerman Stephen Paul, Fried snack pieces and process for preparing.
  14. Zimmerman Stephen Paul ; McDonald Gerald C. ; Hsieh Yen-Ping Chin ; Villagran Maria Dolores Martinez-Serna, Fried snack pieces and process for preparing.
  15. Arimoto, Shin; Uehara, Hidetaka; Negishi, Satoshi, Intermolecular compounds of fatty acid triglycerides.
  16. Nakhasi, Dilip K.; Daniels, Roger L., Low viscosity structured lipid pan release compositions and methods.
  17. Trout, James Earl; Kirkpatrick, Dennis Paul; Romanach, Benito Alberto, Low-moisture, reduced fat, lipid-based fillings.
  18. Teran,Pamela Lynn; Nakhasi,Dilip K.; Shuman,Howard W.; Daniels,Roger L., Low-residue, easy-cleaning and low-viscosity structured lipid pan release compositions and methods.
  19. Nalur Shantha Chandrasekaran, Method of reducing fat in fat-based coating for confectionery products.
  20. Papathanasopoulos,Gus, Micro-molecular hyper-saturation of conventional cooking oils for high altitude and confined space applications.
  21. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
  22. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
  23. Klor Hans-Ulrich Bernhard,DEX ; Hauenschild Annette,DEX, Nutritional composition for the treatment of hypertriglyceridaemia and hyperchylomicronaemia.
  24. Takeuchi, Hiroyuki; Arimoto, Megumi; Asami, Fumie; Taguchi, Nobuo, Oil or fat composition.
  25. Takeuchi,Hiroyuki; Arimoto,Megumi; Asami,Fumie; Taguchi,Nobuo, Oil or fat composition.
  26. Liu Linsen ; Lampert Daniel Scott, Partial interesterification of triacylglycerols.
  27. Wong, Vincent York-Leung; Sackenheim, Richard Joseph; Trout, James Earl; Tavares, Eugene Francisco, Process for making a low-fat nut spread composition.
  28. Walsh Belle Cromwell ; Kester Jeffrey John ; Corrigan Patrick Joseph ; Elsen Joseph James, Process for preparing frozen par-fried potato strips having deep fried texture when oven-finished.
  29. Taylor Kyle McLennan ; Kester Jeffrey John ; Elsen Joseph James ; Corrigan Patrick Joseph ; Biedermann David Thomas ; Papa Alyce Johnson, Process for preparing improved oven-finished french fries.
  30. Walsh Belle Cromwell ; Kester Jeffrey John ; Taylor Kyle McLennan ; Young Herbert Thomas ; Sevenants Michael Robert ; Elsen Joseph James ; Biedermann David Thomas, Process for preparing storage stable par-fries.
  31. Guskey Gerald J. (Montgomery OH) Hellyer James A. (Milford OH), Process for reducing in-mould times for chocolate confections containing reduced calorie fats.
  32. Lin,Peter Yau Tak; Gruber,David Cammiade; Villagran,Maria Dolores Martinez Serna; Seiden,Paul, Processes for making dehydrated starch ingredients.
  33. Naber,Russell Bruce; Kester,Jeffrey John; McRorie, Jr.,Johnson Watson; Adams,Stacey Lynne; Schafermeyer,Richard Gerard, Reduced calorie fat compositions.
  34. Trout, James Earl; Kirkpatrick, Dennis Paul, Reduced fat lipid-based fillings.
  35. Klemann, Lawrence P.; Fine, Jeffrey B.; Kim, Dennis A., Structured glycerol esters useful as edible moisture barriers.
  36. Klemann, Lawrence Paul; Dinwoodie, Robert C., Structured lipid compositions.
  37. Klemann, Lawrence Paul; Dinwoodie, Robert C., Structured lipid compositions.
  38. Klemann, Lawrence Paul; Finley, John Westcott, Structured lipid compositions and methods of formulation thereof.
  39. Nakhasi, Dilip K.; Daniels, Roger L., Structured lipid containing compositions and methods with health and nutrition promoting characteristics.
  40. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
  41. Collard, Joseph; Khorkova Sherman, Olga, Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1.
  42. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ).
  43. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin.
  44. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
  45. Collard, Joseph; Khorkova Sherman, Olga, Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT.
  46. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
  47. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
  48. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
  49. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
  50. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
  51. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
  52. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
  53. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
  54. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
  55. Collard, Joseph; Khorkova Sherman, Olga, Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ).
  56. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
  57. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
  58. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
  59. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
  60. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
  61. Collard, Joseph; Khorkova, Olga, Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1.
  62. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
  63. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
  64. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
  65. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
  66. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
  67. Faghihi, Mohammad Ali; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
  68. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3.
  69. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
  70. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
  71. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
  72. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
  73. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
  74. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
  75. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
  76. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
  77. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
  78. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
  79. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
  80. Collard, Joseph; Khorkova Sherman, Olga, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
  81. Collard, Joseph; Sherman, Olga Khorkova, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
  82. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
  83. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
  84. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity.
  85. Collard, Joseph; Khorkova Sherman, Olga, Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
  86. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
  87. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
  88. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS).
  89. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3).
  90. Collard, Joseph; Khorkova Sherman, Olga, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
  91. Collard, Joseph; Sherman, Olga Khorkova, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
  92. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
  93. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
  94. Collard, Joseph; Khorkova Sherman, Olga, Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
  95. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2.
  96. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
  97. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
  98. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
  99. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
  100. Collard, Joseph; Khorkova Sherman, Olga, Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
  101. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1.
  102. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
  103. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
  104. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
  105. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
  106. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG.
  107. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4.
  108. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; De Leon, Belinda, Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT).
  109. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda; Coito, Carlos; Hsiao, Jane H., Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA.
  110. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
  111. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
  112. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
  113. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
  114. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
  115. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
  116. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
  117. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
  118. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
  119. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
  120. Collard, Joseph; Khorkova Sherman, Olga, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
  121. Collard, Joseph; Sherman, Olga Khorkova, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
  122. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP.
  123. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP.
  124. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로